IBD Evidence

Artiklu

X'jikkawża l-IBD? Ġenetika, ambjent u inċidenza li tikber

Aġġornat 4 min read 60 ċitazzjonijiet

Snare għall-endoskopija tal-wajer użat għall-polipektomija tal-ġiżir u tal-kolon
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

La l-ġenetika u lanqas l-ambjent ma jispjegaw il-marda infjammatorja tal-imsaren waħedhom. Il-ġenetika tgħidlek min huwa suxxettibbli; l-epidemjoloġija tgħidlek li s-suxxettibbiltà waħedha ma tistax tkun l-istorja kollha, għax il-mappa globali tal-marda mxiet malajr wisq biex il-ġeni jistgħu jispjegawha.

X'turi verament il-ġenetika

Studji ta' assoċjazzjoni fuq il-ġenoma kollu identifikaw numru sostanzjali ta' loci assoċjati mas-suxxettibbiltà għall-IBD. Meta-analiżi ta' data ta' assoċjazzjoni identifikat 38 loci ta' suxxettibbiltà u enfasizzat riskju ġenetiku kondiviż fost il-popolazzjonijiet u, notevolment, kondiviż parzjalment ma' mard ieħor medjat mis-sistema immuni [25]. Studju separat ta' assoċjazzjoni fuq il-ġenoma kollu implika attivazzjoni immuni ta' diversi ġeni tal-integrina speċifikament [24] — riżultat interessanti mekkanistikament, peress li mediċini li jimblukkaw l-integrina (il-klassi bijoloġika anti-integrina koperta fil-paġna tagħna dwar it-trattament) jaħdmu billi jinterrompu eżattament il-passaġġ tat-traffikar tal-lewkoċiti li fih jinsabu dawn il-ġeni.

Il-konklużjoni prattika mill-ġenetika hija aktar dejqa milli n-nies jistennew. L-IBD mhijiex marda ta' ġene wieħed, li tintiret b'mod Mendeljan — hija poligenika, b'ħafna loci li kull wieħed jikkontribwixxi ammont żgħir ta' riskju. Li jkollok qarib tal-ewwel grad bl-IBD jgħolli r-riskju 'l fuq mill-popolazzjoni ġenerali, iżda l-maġġoranza l-kbira tan-nies li jġorru varjanti ġenetiċi assoċjati mal-IBD qatt ma jiżviluppaw il-marda. Il-ġenetika tistabbilixxi limitu ta' suxxettibbiltà; xi ħaġa oħra tiddeċiedi jekk dak il-limitu jinqabiżx.

Għaliex il-ġenetika ma tistax tkun l-istorja kollha

L-arkitettura ġenetika ta' popolazzjoni ma tinbidilx fuq ftit deċennji. L-inċidenza globali tal-IBD tinbidel. Analiżi tal-2025 f'*Nature* ittraċċa l-inċidenza tal-IBD fost dak li ssejjaħ stadji epidemjoloġiċi — inċidenza baxxa, fażi ta' aċċelerazzjoni hekk kif l-inċidenza tiżdied b'mod qawwi, imbagħad fażi ta' ekwilibriju kompożizzjonali tal-prevalenza fejn l-inċidenza tistabbilizza iżda n-numru ta' nies li jgħixu bil-marda jibqa' jogħla għax hija kronika [35]. Reġjuni li qed jindustrijalizzaw ġdid illum qed jgħaddu mill-fażi ta' aċċelerazzjoni li l-Ewropa tal-Punent u l-Amerika ta' Fuq għaddew minnha matul is-seklu għoxrin.

Din ix-xejra ġiet iddokumentata qabel f'analiżi sistematika ta' studji bbażati fuq popolazzjoni dwar l-inċidenza u l-prevalenza madwar id-dinja [23], u analiżi oħra li tindirizza speċifikament l-epidemjoloġija matul l-etajiet fl-era ta' terapiji avvanzati tqiegħed l-istampa globali attwali [33]. Analiżi sistematika ffokata fuq l-IBD li tibda fit-tfulija sabet l-istess xejra li qed taċċelera speċifikament fit-tfal u l-adolexxenti [15], u x-xejriet tal-isptar matul l-istess perjodu ġew ikkaratterizzati f'analiżi sistematika oħra b'analiżijiet temporali [7].

Xejra ġeografika u temporali li ssegwi l-industrijalizzazzjoni minflok id-drift ġenetiku hija l-aktar argument qawwi disponibbli li xi ħaġa dwar kif tgħix popolazzjoni — mhux biss kif titwieled — qed tagħmel parti sostanzjali mix-xogħol kawżali.

Il-kandidati ambjentali

Analiżi ġenerali ta' meta-analiżijiet eżaminat direttament fatturi ta' riskju ambjentali għall-IBD, u ġġabbret l-evidenza minn ħafna studji individwali ta' esponiment f'sinteżi waħda [20]. Is-sommarju onest ta' din il-letteratura huwa li diversi kandidati għandhom evidenza ta' appoġġ ta' qawwa varjabbli, u l-ebda wieħed ma ntwera li huwa suffiċjenti waħdu — konsistenti ma' marda li plawżibbilment teħtieġ li individwu ġenetikament suxxettibbli jiltaqa' ma' kombinazzjoni partikolari ta' esponimenti.

L-assi waħda: kif jaqblu l-biċċiet flimkien

Kategorija ta' fatturDak li huwa stabbilitDak li mhuwiex
Suxxettibbiltà ġenetikaĠew identifikati għexieren ta' loci li jikkontribwixxu; ir-riskju jinġabar fil-familji u jaqsam mekkaniżmi ma' mard immuni ieħorL-ebda ġene waħdu mhu meħtieġ jew suffiċjenti; il-biċċa l-kbira tan-nies ġenetikament suxxettibbli qatt ma jiżviluppaw l-IBD
Xejra ġeografika/temporaliL-inċidenza tiżdied b'mod qawwi hekk kif ir-reġjuni jindustrijalizzaw, imbagħad tistabbilizza filwaqt li l-prevalenza tibqa' tiela'Ix-xejra turi li l-ambjent jimporta; ma tidentifikax waħedha liema esponiment jimporta l-aktar
Esponimenti ambjentali individwaliAnaliżi ġenerali sintetizzat il-letteratura tal-esponiment fost ħafna fatturi kandidatiL-ebda fattur ambjentali waħdu mhu stabbilit bħala meħtieġ jew suffiċjenti waħdu
L-interazzjoniPlawżibbli u konsistenti max-xejra ġenerali tad-data: suxxettibbiltà flimkien ma' esponimentMhux imkejjel direttament bid-disinji attwali tal-istudji fil-livell individwali

Għaliex dan jimporta prattikament

Xejn minn dan ma jbiddel il-ġestjoni. Ma jidentifikax ikel x'għandek tevita, bidla fl-istil ta' ħajja ggarantita li tipprevjeni l-fjammati, jew test li jbassar ir-riskju individwali b'preċiżjoni utli. Dak li jispjega huma żewġ affarijiet li l-pazjenti spiss jingħataw b'mod inkonsistenti: li l-IBD mhijiex "ikkawżata" mid-dieta jew l-istress fi kwalunkwe sens sempliċi (il-ġenetika u l-bidliet ambjentali fil-livell tal-popolazzjoni qed jagħmlu ħafna aktar mix-xogħol kawżali mill-għażliet ta' kuljum), u li lanqas mhi purament xorti ħażina ġenetika (l-inċidenza li qed togħla f'reġjuni li qed jindustrijalizzaw ġdid teskludi dan waħidha). Iż-żewġ riformulazzjonijiet ġeneralment inaqqsu l-ħtija li l-pazjenti jirrappurtaw dwar "x'għamilt biex ikkawżajt dan" — mistoqsija li l-bażi ta' evidenza fil-fatt ma tappoġġax li ssir dwar kwalunkwe mġiba waħda.

Mistoqsijiet komuni

L-IBD hija ereditarja? It-tfal tiegħi se jieħduha?
Ir-riskju huwa elevat f'qraba tal-ewwel grad ta' xi ħadd bl-IBD, iżda l-maġġoranza l-kbira tal-qraba qatt ma jiżviluppawha. Hija xejra ta' ġeni ta' suxxettibbiltà, mhux marda li tintiret b'mod Mendeljan.
Xi ħaġa li kilt jew għamilt ikkawżat l-IBD tiegħi?
L-ebda fattur djetetiku jew tal-istil ta' ħajja waħdu ma ġie stabbilit bħala kawża suffiċjenti. L-evidenza tindika kombinazzjoni ta' suxxettibbiltà ġenetika u esponimenti ambjentali fil-livell tal-popolazzjoni li jseħħu fuq snin, mhux xprun individwali identifikabbli.
Għaliex l-IBD qed issir aktar komuni f'pajjiżi fejn qabel kienet rari?
Dan isegwi l-industrijalizzazzjoni mill-qrib biżżejjed li huwa wieħed mill-aktar argumenti qawwija għal komponent ambjentali — il-ġeni ma jinbidlux malajr biżżejjed biex jispjegawh, u x-xejra issa ġiet iddokumentata fost diversi reġjuni u perjodi ta' żmien.
Jekk il-ġenetika tispjega biss is-suxxettibbiltà, x'inhu t-trigger attwali?
Mhux stabbilit b'preċiżjoni. Espożizzjonijiet ambjentali kandidati ġew sintetizzati f'evidenza ta' reviżjoni umbrella, iżda l-ebda fattur wieħed ma wera li huwa meħtieġ jew biżżejjed — dan jibqa' qasam ta' riċerka miftuħ pjuttost milli mistoqsija solvuta.
Tliet kapsuli bil-kamera użati biex jimmaġġjaw l-esofagu, il-musrana ż-żgħira u l-musrana l-kbira
Kapsuli mibluha jieħdu ritratti ta' partijiet tal-musrana ż-żgħira li endoskopju konvenzjonali ma jistax jilħaq. Dr.HH.Krause · CC BY-SA 3.0 · Wikimedia Commons

Qari relatat

Il-provi li hemm wara din il-paġna Bar imwaħħal li juri l-kompożizzjoni tal-30 pubblikazzjoni msemmija f'din il-paġna skont it-tip ta' studju. 2563meta-analysis (25)randomised trial (6)review (3)other (1)
35 pubblikazzjonijiet, 2015–2026. Dan huwa ammont li jinkludi kemm provi kif ukoll sinteżi, li huwa l-pożizzjoni minn fejn talba dwar il-kawża hija raġonevoli. Sors: il-lista ta' ċitazzjonijiet ta' din il-paġna, hawn taħt.

Referenzi

Kull ċitazzjoni hawn taħt tgħaqqad mal-record oriġinali peer-reviewed fuq PubMed jew permezz ta' DOI. Xejn hawnhekk m'għandux ikun sostitut għal parir mediku.

  1. Dual biologics or combination therapy with small molecules in pediatric inflammatory bowel disease: a systematic review and meta-analysis Huo BL, Zhao AL, Liu W, et al. · World journal of pediatrics : WJP · 2026 · Meta-analysis DOIPubMed 42387245
  2. Mediterranean diet in treatment of inflammatory bowel disease: A systematic review and meta-analysis Singh A, Rana U, Chandnani S, et al. · Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026 · Meta-analysis DOIPubMed 41803562
  3. Study Design Complexity and Participant Completion in Dietary Trials for Inflammatory Bowel Disease: A Systematic Review and Metaresearch Study Gregersen L, Moos C, Hikmat Z, et al. · Advances in nutrition (Bethesda, Md.) · 2026 · Systematic review DOIPubMed 41825595Full text
  4. Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies Halim A, Ho AHY, Wanchaitanawong W, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Meta-analysis DOIPubMed 41577066
  5. Blood Bile Acids for Inflammatory Bowel Disease Diagnosis and Disease Activity Assessment: A Metabolomics Meta-Analysis Thu NQ, An VT, Dat LHB, et al. · Journal of proteome research · 2026 · Meta-analysis DOIPubMed 42695907
  6. Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis Moraes BF, Leite GAPD, Visentini LM, et al. · Journal of Crohn's & colitis · 2026 · Meta-analysis DOIPubMed 41874976
  7. The Role of Inflammation in Infant Colic-A Systematic Review and Meta-Analysis Andersen DB, Fog J, Vestergaard MV, et al. · Acta paediatrica (Oslo, Norway : 1992) · 2026 · Meta-analysis DOIPubMed 41803938Full text
  8. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  9. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  10. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  11. Pre-Illness Index-Based Dietary Patterns and Inflammatory Bowel Disease Risk: A Systematic Review and Meta-Analysis Meng F, Zhang T, Meng X, et al. · Nutrition reviews · 2025 · Meta-analysis DOIPubMed 40700526
  12. Using Diet to Treat Inflammatory Bowel Disease: A Systematic Review Gleave A, Shah A, Tahir U, et al. · The American journal of gastroenterology · 2025 · Systematic review DOIPubMed 39056556
  13. Efficacy of a Low-FODMAP Diet on the Severity of Gastrointestinal Symptoms and Quality of Life in the Treatment of Gastrointestinal Disorders-A Systematic Review of Randomized Controlled Trials Kuźmin L, Kubiak K, Lange E · Nutrients · 2025 · Systematic review DOIPubMed 40573159Full text
  14. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  15. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes Zheng T, Roda G, Zabana Y, et al. · Journal of Crohn's & colitis · 2024 · Meta-analysis DOIPubMed 37768647
  16. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  17. Efficacy of different dietary therapy strategies in active pediatric Crohn's disease: a systematic review and network meta-analysis Ma J, Chong J, Qiu Z, et al. · PeerJ · 2024 · Meta-analysis DOIPubMed 39686992Full text
  18. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  19. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  20. Features of paradoxical psoriasis and risk factors in inflammatory bowel disease: A systematic review and meta-analysis Croitoru DO, Brooks SG, Nathanielsz N, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2023 · Meta-analysis DOIPubMed 36912825
  21. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  22. High-Fiber Diet and Crohn's Disease: Systematic Review and Meta-Analysis Serrano Fernandez V, Seldas Palomino M, Laredo-Aguilera JA, et al. · Nutrients · 2023 · Meta-analysis DOIPubMed 37513532Full text
  23. Dietary Interventions in Ulcerative Colitis: A Systematic Review of the Evidence with Meta-Analysis Herrador-López M, Martín-Masot R, Navas-López VM · Nutrients · 2023 · Meta-analysis DOIPubMed 37836478Full text
  24. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  25. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  26. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  27. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  28. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  29. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  30. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease Sinopoulou V, Gordon M, Akobeng AK, et al. · The Cochrane database of systematic reviews · 2021 · Systematic review DOIPubMed 34844288Full text
  31. Systematic Review of the Effects of Oat Intake on Gastrointestinal Health Valido E, Stoyanov J, Bertolo A, et al. · The Journal of nutrition · 2021 · Systematic review DOIPubMed 34486656
  32. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  33. Incidence of SARS-CoV-2 infection in inflammatory bowel disease Lee MH, Ng CH, Chin YH, et al. · Journal of gastroenterology and hepatology · 2020 · Meta-analysis DOIPubMed 32779774Full text
  34. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  35. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses Piovani D, Danese S, Peyrin-Biroulet L, et al. · Gastroenterology · 2019 · Meta-analysis DOIPubMed 31014995
  36. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  37. ESPEN guideline: Clinical nutrition in inflammatory bowel disease Forbes A, Escher J, Hébuterne X, et al. · Clinical nutrition (Edinburgh, Scotland) · 2017 · Systematic review DOIPubMed 28131521
  38. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  39. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  40. Inflammatory bowel disease and risk of stroke: A meta-analysis of cohort studies Yuan M, Zhou HY, Xiao XL, et al. · International journal of cardiology · 2016 · Meta-analysis DOIPubMed 26386936
  41. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS Menees SB, Powell C, Kurlander J, et al. · The American journal of gastroenterology · 2015 · Meta-analysis DOIPubMed 25732419
  42. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text
  43. Consumption of vegetables and fruit and the risk of inflammatory bowel disease: a meta-analysis Li F, Liu X, Wang W, et al. · European journal of gastroenterology & hepatology · 2015 · Meta-analysis DOIPubMed 25831134
  44. Fecal lactoferrin in discriminating inflammatory bowel disease from irritable bowel syndrome: a diagnostic meta-analysis Zhou XL, Xu W, Tang XX, et al. · BMC gastroenterology · 2014 · Meta-analysis DOIPubMed 25002150Full text
  45. Effect of Five Dietary Emulsifiers on Inflammation, Permeability, and the Gut Microbiome: A Placebo-controlled Randomized Trial Wellens J, Vanderstappen J, Hoekx S, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026 · Randomised controlled trial DOIPubMed 40816342
  46. A Randomised Controlled Trial Comparing the Effects of Personalised Diet and Physical Activity Intervention Versus Usual Care on Cardiometabolic Risk Factors in Adults with Inactive Inflammatory Bowel Disease Yap JM, Wall CL, Meredith-Jones K, et al. · Nutrients · 2026 · Randomised controlled trial DOIPubMed 41829955Full text
  47. Evidence for a Modulatory Effect of a 12-Week Pomegranate Juice Intervention on the Transcriptional Response in Inflammatory Bowel Disease Patients Reducing Fecal Calprotectin Levels: Findings From a Proof-of-Principle Study Minato I, Mena P, Ricciardiello L, et al. · Molecular nutrition & food research · 2025 · Randomised controlled trial DOIPubMed 40255128Full text
  48. Effects of bromelain supplementation on disease activity and quality of life in patients with ulcerative colitis: a randomized, triple-blind, placebo-controlled study Delgarm P, Mokhtare M, Ebrahimi Daryani N, et al. · Scientific reports · 2025 · Randomised controlled trial DOIPubMed 41315628Full text
  49. Whole Food Diet Induces Remission in Children and Young Adults With Mild to Moderate Crohn's Disease and Is More Tolerable Than Exclusive Enteral Nutrition: A Randomized Controlled Trial Aharoni-Frutkoff Y, Plotkin L, Pollak D, et al. · Gastroenterology · 2025 · Randomised controlled trial DOIPubMed 40553742
  50. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial Pasta A, Formisano E, Calabrese F, et al. · European journal of clinical investigation · 2025 · Randomised controlled trial DOIPubMed 39853756
  51. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  52. The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial Yanai H, Levine A, Hirsch A, et al. · The lancet. Gastroenterology & hepatology · 2022 · Randomised controlled trial DOIPubMed 34739863
  53. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  54. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition Svolos V, Hansen R, Nichols B, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 30550821
  55. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial Levine A, Wine E, Assa A, et al. · Gastroenterology · 2019 · Randomised controlled trial DOIPubMed 31170412
  56. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  57. Chronic, Noninfectious Diarrhea: A Review Singh P, Lee A, Sheth NM, et al. · JAMA · 2026 · Review DOIPubMed 41770539
  58. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  59. Mild Crohn's Disease: Definition and Management Claytor J, Kumar P, Ananthakrishnan AN, et al. · Current gastroenterology reports · 2023 · Review DOIPubMed 36753033
  60. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text

Din il-paġna ġiet tradotta awtomatikament mill-Ingliż. Il-citazzjonijiet u n-numri mhumiex mibdula. Aqra l-original Ingliż jekk xi ħaġa taqra b'mod stramb. Aqra l-original Ingliż